US Stock Market Move | ZAI LAB (ZLAB.US) surged over 12%, with Q2 product revenue increasing by 11% quarter-on-quarter.

On Thursday, ZAI LAB (ZLAB.US) surged over 12% to $20.68. In terms of news, ZAI LAB announced its financial performance for the second quarter of 2026. The financial report showed that the total revenue for the second quarter of 2026 was $106.3 million, with net product revenue of $105.8 million, an 11% quarter-over-quarter increase, thanks to the stable performance of Zevorel and the continued growth in sales of Eptinezumab. While the commercialization fundamentals are robust and improving, the company has also seen significant regulatory progress in its oncology pipeline. Among these, the ADC drug Zocilurtatug Pelitecan (ZOCI) has stood out. In July 2026, ZAI LAB received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for ZOCI for the treatment of neuroendocrine cancers (NECs). In June, ZAI LAB obtained orphan drug designation from the European Medicines Agency (EMA) for ZOCI for the treatment of patients with lung neuroendocrine cancer. In May, ZAI LAB received fast track designation (FTD) from the FDA for ZOCI for the treatment of patients with extraneural neuroendocrine cancers (epNECs). This is the second FDA fast track designation obtained for ZOCI, and the company is actively communicating with regulatory agencies to advance its registration plan for the treatment of epNECs.